(redirected from Immunoglobulin A Nephropathy)
Also found in: Dictionary, Thesaurus, Medical, Acronyms.


Any disease of the kidney.
McGraw-Hill Dictionary of Scientific & Technical Terms, 6E, Copyright © 2003 by The McGraw-Hill Companies, Inc.
The following article is from The Great Soviet Encyclopedia (1979). It might be outdated or ideologically biased.



a general term that includes several renal disorders. Classified as nephropathies are nephropathy of pregnancy and a group of other kidney diseases that are distinguished from each other by a variety of morphological changes. This latter group of diseases includes myelogenous nephropathy, endemic, or Balkan, nephropathy, medicinally induced nephropathy, kaliopenic nephropathy, and hypercalcemic nephropathy.


Osnovy nefrologii, vol. 2. Edited by E. M. Tareev. Moscow, 1972.
The Great Soviet Encyclopedia, 3rd Edition (1970-1979). © 2010 The Gale Group, Inc. All rights reserved.
References in periodicals archive ?
Takei, T., Iida A, Nitta K, Tanaka T, Ohnishi Y, Yamada R, Maeda S, Tsunoda T, Takeoka S, Ito K, Honda K, Uchida K, Tsuchiya K, Suzuki Y, Fujioka T, Ujiie T, Nagane Y, Miyano S, Narita I, Gejyo F, Nihei H, Nakamura Y., Association between Single Nucleotide Polymorphisms in Selectin Genes and Immunoglobulin A Nephropathy. Am.
Three OMS721 Phase 3 clinical programs are progressing across hematopoietic stem cell transplant-associated thrombotic microangiopathy, immunoglobulin A nephropathy, and atypical hemolytic uremic syndrome.
The data are from study patients with immunoglobulin A nephropathy, a progressively worsening kidney disease and the most common glomerulonephritis worldwide, responsible for 10% of all people on dialysis globally.
Omeros Corporation announced that the European Medicines Agency's Committee for Orphan Medicinal Products issued a positive opinion on Omeros' application for orphan drug designation of OMS721 in the treatment of primary Immunoglobulin A nephropathy. OMS721 is Omeros' lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2, the effector enzyme of the lectin pathway of the complement system, and is in Phase 3 development for each of IgAN, atypical hemolytic uremic syndrome, and hematopoietic stem cell transplant-associated thrombotic microangiopathy.
There are three Phase 3 development programs ongoing with OMS721 in each of HSCT-associated thrombotic microangiopathy, atypical hemolytic uremic syndrome, and immunoglobulin A nephropathy.